Pitavastatin-d5 Lactone

CAS: 141750-63-2

Ref. TR-P531022

Produktinformation

• Name: Pitavastatin-d5 Lactone
• Synonyme: (4R,6S)-6-[(1E)-2-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one, [4R-[4a,6ß(E)]]-6-[2-[2-(Cyclopropyl-d5)-4- (4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one, NK 104-d5, NK 104-d5 (lactone), Nisvastatin-d5, P 872441-d5, 4-(1-(4-Chlorobenzoyl)-6-imino-3-methyl-1,4,6,7-tetrahydropyrazolo[3,4-d][1,3]thiazin-4-yl)-2-methoxyphenol, 4H-Pyrazolo[3,4-d][1,3]thiazin-6-amine, 1-(4-chlorobenzoyl)-4-(4-hydroxy-3-methoxyphenyl)-3-methyl-, [6-amino-4-(4-hydroxy-3-methoxyphenyl)-3-methylpyrazolo[3,4-d][1,3]thiazin-1(4H)-yl](4-chlorophenyl)methanone, (4R,6S,E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl-ethenylvinyl]-4-hydroxyl-3,4,5,6-H-2H-pyran-2-etone, Pitavastatin calcium intermediates to 5,(4R,6S,E)-6-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinoline-yl-vinyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Beschreibung

Applications A labelled metabolite of Pitavastatin. Recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells.
References Wang, J., et al.: Drug Metab. Dispos., 30, 1352 (2002), Yamada, I., et al.: Xenobiotica, 33, 789 (2003), Fujino, H., et al.: Xenobiotica, 34, 961 (2004), Ando, H., et al.: Br. J. Clin. Pharmacol., 60, 494 (2005),

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 408.48
• Formel: C₂₅H₁₇D₅FNO₃
• Farbe/Form: Neat
• InChl: InChI=1S/C25H22FNO3/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-19-13-18(28)14-23(29)30-19/h1-4,7-12,16,18-19,28H,5-6,13-14H2/b12-11+/t18-,19-/m1/s1/i5D2,6D2,16D
• InChI Key: InChIKey=XJVKVAFYQRWVAJ-RNMTVWSWSA-N
• SMILES: [2H]C1([2H])C([2H])([2H])C1([2H])c1nc2ccccc2c(-c2ccc(F)cc2)c1/C=C/[C@@H]1C[C@@H](O)CC(=O)O1